Synapse - Robert Motzer

Results (1247)

Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)

Meeting Abstract

Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study

Meeting Abstract

Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial

Meeting Abstract

Eto, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Oya, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

292P Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial

Meeting Abstract

Oya, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Eto, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Management of kidney cancer relapse to adjuvant pembrolizumab: Early insights and questions for a newly emerging space

Editorial

Voss, M. H.; Motzer, R. J.
European Urology (2024)

Fulltext@MSK | Save

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial

Journal Article

Choueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; more...
ESMO Open (2024)

Fulltext@MSK | Save

Lenvatinib plus Pembrolizumab following immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma: Results from study 111/KEYNOTE-146

Research Letter

Lee, C. H.; Yogesh Shah, A.; Rao, A.; Taylor, M. H.; Di Simone, C.; Hsieh, J. J.; Pinto, A.; Gironés Sarrió, R.; Lee Cohn, A.; Asim Bilen, M.; more...
European Urology (2024)

Fulltext@MSK | Save

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study

Journal Article

Choueiri, T. K.; Albiges, L.; Barthélémy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P.; Basu, A.; Bourlon, M. T.; more...
Lancet (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Journal Article

Tannir, N. M.; Albigès, L.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthélémy, P.; Plimack, E. R.; Porta, C.; George, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial

Meeting Abstract

Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save